Abstract:Chemokines are chemotactic cytokines that promote cancer growth, metastasis, and regulate resistance to chemotherapy. Stromal cell-derived factor 1 (SDF1) also known as C-X-C motif chemokine 12 (CXCL12), a prognostic factor, is an extracellular homeostatic chemokine that is the natural ligand for chemokine receptors C-X-C chemokine receptor type 4 (CXCR4), also known as fusin or cluster of differentiation 184 (CD184) and chemokine receptor type 7 (CXCR7). CXCR4 is the most widely expressed rhodopsin-like G protein coupled chemokine receptor (GPCR). The CXCL12–CXCR4 axis is involved in tumor growth, invasion, angiogenesis, and metastasis in colorectal cancer (CRC). CXCR7, recently termed as atypical chemokine receptor 3 (ACKR3), is amongst the G protein coupled cell surface receptor family that is also commonly expressed in a large variety of cancer cells. CXCR7, like CXCR4, regulates immunity, angiogenesis, stem cell trafficking, cell growth and organ-specific metastases. CXCR4 and CXCR7 are expressed individually or together, depending on the tumor type. When expressed together, CXCR4 and CXCR7 can form homo- or hetero-dimers. Homo- and hetero-dimerization of CXCL12 and its receptors CXCR4 and CXCR7 alter their signaling activity. Only few drugs have been approved for clinical use targeting CXCL12-CXCR4/CXCR7 axis. Several CXCR4 inhibitors are in clinical trials for solid tumor treatment with limited success whereas CXCR7-specific inhibitors are still in preclinical studies for CRC. This review focuses on current knowledge of chemokine CXCL12 and its receptors CXCR4 and CXCR7, with emphasis on targeting the CXCL12–CXCR4/CXCR7 axis as a treatment strategy for CRC.

Potential of CXCR4/CXCL12 Chemokine Axis in Cancer Drug Delivery

The Role of the CXCL12/CXCR4/CXCR7 Chemokine Axis in Cancer

A review on CXCR4/CXCL12 axis in oncology: No place to hide

CXC chemokine receptor 4 (CXCR4) blockade in cancer treatment

The role of CXCL12 in tumor microenvironment

CXCL12-CXCR4/CXCR7 Axis in Cancer: from Mechanisms to Clinical Applications

Promise of Chemokine Network‐targeted Nanoparticles in Combination Nucleic Acid Therapies of Metastatic Cancer

Targeting CXCR1/2: The medicinal potential as cancer immunotherapy agents, antagonists research highlights and challenges ahead

Oncogenic roles and drug target of CXCR4/CXCL12 axis in lung cancer and cancer stem cell

Potential Role of CXCR4 Targeting in the Context of Radiotherapy and Immunotherapy of Cancer

The Chemokine CXCL14 as a Potential Immunotherapeutic Agent for Cancer Therapy

CXCL12-CXCR4/CXCR7 Axis in Colorectal Cancer: Therapeutic Target in Preclinical and Clinical Studies

CXCL12/CXCR4: a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks

CXCR4-Targeted Radiopharmaceuticals for the Imaging and Therapy of Malignant Tumors

Pharmacological intervention at CCR1 and CCR5 as an approach for cancer: help or hindrance

The Role of CXCL11 and its Receptors in Cancer: Prospective but Challenging Clinical Targets

The Role of CXC Chemokine Receptors 1–4 on Immune Cells in the Tumor Microenvironment

Role of the CCL2‐CCR2 signalling axis in cancer: Mechanisms and therapeutic targeting

Potential anticancer therapies via CXCL5 and its receptors.

A promising strategy of surface-modified nanoparticles targeting CXCR4 for precision cancer therapy

CXCR3 As a Molecular Target in Breast Cancer Metastasis: Inhibition of Tumor Cell Migration and Promotion of Host Anti-Tumor Immunity